hrp0084p3-779 | Diabetes | ESPE2015

Effects of Educational Interventions for Children and Adolescents with Type 1 Diabetes Mellitus

Atef Abeer , Attia Mona , Ibrahim Amany , Ibrahim Shaimaa , Dowidar Wafaa , Tawfik Sameh

Background: Is to evaluate of the quality of the current education program for diabetic children and their parents at Diabetes Endocrine and Metabolism Pediatric Unit (DEMPU).Objective and hypotheses: Is to evaluate of the quality of the current education program for diabetic children and their parents at DEMPU.Method: The present study was an observational longitudinal study conducted on 100 cases of T1D admitted in DEMPU inpatien...

hrp0094p2-337 | Multisystem endocrine disorders | ESPE2021

Van Wyk Grumbach Syndrome in an Egyptian Female Pediatric Patient: a rare presentation of a common disease

Ibrahim Amany , Abdel Rahman Alshaimaa Mahfouz ,

Background: Van Wyc-Grumbach syndrome is a rare presentation of long standing pre-pubertal hypothyroidism characterized by bilateral multicystic ovaries, vaginal bleeding and delayed skeletal growth in case of female.Case Presentation: we present a clinical course, diagnosis and management of a case of Van Wyc-Grumbach syndrome in a 10-years old Egyptian counselled for recurrent vaginal bleeding and pubertal advancement for age. She was ...

hrp0092rfc7.3 | Diabetes and Insulin Session 2 | ESPE2019

Osteopontin as an Early Urinary Marker of Diabetic Nephropathy in Adolescents with Type 1 Diabetes Mellitus

Ibrahim Amany , Soliman Hend , Abdullatif Mona , Sabry Aly

Introduction: Patients with type 1 diabetes (T1D) have a higher rate of morbidity and mortality compared with the general population, which varies across countries. Diabetic nephropathy (DN) is a common and serious complication of T1D. Osteopontin (OPN) is a calcium binding phosphoprotein that is expressed in glomerular basement membrane. OPN can be a potential marker of vasculopathy and subclinical atherosclerosis and hence a predictor of DN in T1D patients. ...

hrp0092p1-34 | Diabetes and Insulin | ESPE2019

Serum Dipeptidyl peptidase-4 Activity and its Relation to Insulin Resistance in Type 1 Diabetic Adolescents

Hana Mona , Madani Hanan , Ibrahim Amany , Soliman Hend , Salah Shimaa

Background: Insulin resistance (IR) plays a larger role in type 1 diabetes (T1D) disease process than is commonly recognized. Dipeptidyl peptidase-4 (DPP-4) is an enzyme that is expressed on almost all cell surfaces. It deactivates many bioactive peptides involved in glucose regulation; glucose-dependent insulinotropic polypeptide and Glucagon-like peptide-1.Objectives: This study evaluates serum DPP-4 activity in adoles...

hrp0092p1-141 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology | ESPE2019

Diagnostic Value of Anti-Mullerian Hormone Level in Adolescent Females with Polycystic Ovary Syndrome

Abdelghaffar Shereen , Ibrahim Amany , Rabie Walaa , Mohammed Asmaa

In adolescence, diagnosis of polycystic ovary syndrome (PCOS) is challenging because characteristics of normal puberty often overlap with signs and symptoms of PCOS. Anti-Müllerian hormone (AMH) is one of the important biomarkers suggested to confirm the diagnosis of PCOS and to manage the treatment process in adolescence. The aim of this study was to evaluate the diagnostic role of anti-müllerian hormone for PCOS in adolescent females, and to study its association t...

hrp0089p2-p257 | Growth & Syndromes P2 | ESPE2018

Clinical Effectiveness and Cost-Effectiveness of Somatropin Treatment for Short Children in Egypt: Analysis of 1-Year Data

Ibrahim Amany , Atef Abeer , Badawy Nora , Helmy Eatemad

Recombinant human growth hormone (rhGH) is approved for short stature associated with growth hormone deficiency (GHD), idiopathic short stature (ISS), Turner syndrome (TS), multiple pituitary hormone deficiencies (MPHD), Silver Russell syndrome (SRS) and being born small for gestational age non syndromic (SGA). Objectives: To assess the clinical effectiveness and cost-effectiveness of rhGH in children with GHD, TS and those born SGA. Methods: ...

hrp0086p2-p310 | Diabetes P2 | ESPE2016

Diabetic Ketoacidosis: Clinical Features and Precipitating Factors at DEMPU

Ibrahim Amany , Hassan Mona Mamdouh , Arafa Noha , Eldin Asmaa Salah

Background: Diabetic ketoacidosis (DKA) is an acute complication of type 1 diabetes mellitus (T1DM) that can be fatal if not properly managed. DKA is a leading cause of mortality in these children, early recognition and prompt treatment should substantially reduce childhood mortality in children with T1DM.Objective and hypotheses: We aimed to identify the risk factors and the most common clinical features of newly diagnosed diabetes in children, in addit...

hrp0086p2-p861 | Syndromes: Mechanisms and Management P2 | ESPE2016

The Effect of Iron Intervention on the Anthropometric Parameters: Pilot Study among Egyptian Preschool Children with Iron Deficiency Anemia

Ibrahim Amany , Atef Abeer , Magdy Rania , Farag Mohamed

Background: Iron deficiency anemia (IDA) causes detrimental effects on physical growth which is attributed to poor appetite, altered endocrinologic profile and neurotransmitter metabolism consequent to iron deficiency.Objective and hypotheses: To investigate the iron status of preschool children with IDA and its association with the degree of growth retardation at presentation, and to detect the effect of iron supplementation on growth velocity (GV) over...

hrp0084p3-769 | Diabetes | ESPE2015

Cutaneous Manifestations among Type 1 Diabetic Patients in DEMPU

Youssef Randa , Ibrahim Amany , Amin Iman , Naser Amany Abd El

Background: Almost all diabetic patients eventually develop skin complications from the long-term effects of diabetes mellitus. Cutaneous manifestations generally appear subsequent to the development of diabetes but may be the first presenting sign, or even precede the diagnosis.Objective and hypotheses: To detect the prevalence and spectrum of skin manifestations in type 1 diabetic (T1D) patients attending the Diabetes Endocrine and Metabolism Pediatric...

hrp0097p1-132 | Growth and Syndromes | ESPE2023

One-year growth response and cost-effectiveness to Human recombinant growth hormone in girls with Turner Syndrome: Results from a large Egyptian retrospective study

Ibrahim Amany , Atef Abeer , Badawi Nora , Yassin Sahar , Helmy Eatemad

FDA licensed the use of human recombinant growth hormone (hGH) in girls with Turner Syndrome (TS) in 1997 as short stature is a consistent feature of this syndrome.Objective: we aimed to assess our 1-year experience of treating short girls with TS, to calculate their growth velocity, to analyze the patients’ characteristics and to investigate the possible factors that might affect their height gain.Me...